{"paper_id":"586be1e2-0c2e-4168-8676-989197a6b8cd","body_text":"Abstract\nEndometriosis is an angiogenesis-dependent disease. Many studies demonstrated inhibition of angiogenesis leads to inhibition of endometriotic growth, however underlying mechanism is still not fully understood. Our previous study suggested vascular endothelial growth factor C (VEGF-C) as a target of anti-angiogenesis therapy for endometriosis. In this study, VEGF-C in endometrium and its role in angiogenesis of endometriosis were studied. Human endometrium were obtained from women with and without endometriosis for molecular studies. VEGF-A, VEGF-B, VEGF-C and VEGF-D mRNA and proteins in eutopic and ectopic endometrium were measured. Human endothelial cells were transfected with VEGF-C siRNA in vitro, effects of VEGF-C on endothelial cell migration, invasion and tube formation were investigated in vitro. Angiogenesis was inhibited in wild type mice, vascular permeability in dermal skin was determined in vivo. Transplanted endometrium were inhibited by VEGF-C siRNA in immunocompromised mice, development, growth and angiogenesis of the experimental endometriosis were compared in vivo. The results showed that VEGF-C mRNA and protein were increased in eutopic and ectopic endometrium of endometriosis patients. VEGF-C siRNA significantly inhibited endothelial cell migration and tube formation. VEGF-C siRNA significantly inhibited development and angiogenesis of the experimental endometriotic lesions in mice. Supplementation and over-expression of VEGF-C significantly reversed the inhibitory effects on the endothelial functions, vascular permeability and endometriotic growth. In conclusion, VEGF-C is increased in endometrium and it promotes endothelial functions, vascular permeability and development of experimental endometriosis. VEGF-C is important for angiogenesis in endometriosis.\nSimilar content being viewed by others\nReferences\nRisau W (1997) Mechanisms of angiogenesis. Nature 386:671–674\nTaylor RN, Lebovic DI, Mueller MD (2002) Angiogenic factors in endometriosis. Ann N Y Acad Sci 955:89–100\nNisolle M, Casanas-Roux F, Anaf V, Mine JM, Donnez J (1993) Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil Steril 59:681–684\nBecker CM, Rohwer N, Funakoshi T, Cramer T, Bernhardt W, Birsner A, Folkman J, D’Amato RJ (2008) 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol 172:534–544\nXu H, Lui WT, Chu CY, Ng PS, Wang CC, Rogers MS (2009) Anti-angiogenic effects of green tea catechin on an experimental endometriosis mouse model. Hum Reprod 24:608–618\nBecker CM, Sampson DA, Short SM, Javaherian K, Folkman J, D’Amato RJ (2006) Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertil Steril 85:71–77\nGroothuis PG, Nap AW, Winterhager E, Grümmer R (2005) Vascular development in endometriosis. Angiogenesis 8:147–156\nFolkman J, Klagsbrun M (1987) Angiogenic factors. Science 235:442–447\nCarmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307\nKeck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309–1312\nFerrara N (2009) VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 20:158–163\nNagy JA, Dvorak AM, Dvorak HF (2007) VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2:251–275\nVeikkola T, Alitalo K (1999) VEGFs, receptors and angiogenesis. Sem Cancer Biol 9:211–220\nFerrara N (1999) Vascular endothelial growth factor: molecular and biological aspects. Curr Topics Microbiol Immunol 237:1–30\nDonnez J, Smoes P, Gillerot S, Casanas-Roux F, Nisolle M (1998) Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod 13:1686–1690\nMcLaren J (2000) Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 6:45–55\nHull ML, Charnock-Jones DS, Chan CL, Bruner-Tran KL, Osteen KG, Tom BD, Fan TP, Smith SK (2003) Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab 88:2889–2899\nXu H, Becker CM, Lui WT, Chu CY, Davis TN, Kung AL, Birsner AE, D’Amato RJ, Wai Man GC, Wang CC (2011) Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo. Fertil Steril 96:1021–1028\nJoukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K (1996) A novel endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:290–298\nLee J, Gray A, Yuan J, Luoh SM, Avraham H, Wood WI (1996) Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 93:1988–1992\nKukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, Alitalo K (1996) VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122:3829–3837\nAmerican Society for Reproduction Medicine (1997) Revised American Society for Reproduction Medicine classification of endometriosis: 1996. Fertil Steril 67:817–821\nNap AW, Griffioen AW, Dunselman GAJ, Bouma-TerSteege JCA, Tijssen VJL, Evers JLH, Groothuis PG (2004) Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab 89:1089–1095\nBruner-Tran KL, Osteen KG, Duleba AJ (2009) Simvastatin protects against the development of endometriosis in a nude mouse model. J Clin Endocrinol Metab 94:2489–2494\nBecker CM, Sampson DA, Rupnick MA, Rohan RM, Efstathiou JA, Short SM, Taylor GA, Folkman J, D’Amato RJ (2005) Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 84(Suppl 2):1144–1155\nRistimaki A, Narko K, Enholm B, Joukov V, Alitalo K (1998) Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem 273:8413–8418\nKeichel S, Barcena de rellano ML, Reichelt U, Riedlinger WF, Schneider A, Köhler C, Mechsner S (2011) Lymphangiogenesis in deep infiltrating endometriosis. Hum Reprod 26:2713–2720\nJeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K (1997) Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276:1423–1425\nPepper MS, Mandriota SJ, Jeltsch M, Kumar V, Alitalo K (1998) Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J Cell Physiol 177:439–452\nJoukov V, Sorsa T, Kumar V, Jelisch M, Claesson-welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K (1997) Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 16:3898–3911\nAdya R, Tan BK, Punn A, Chen J, Randeva HS (2008) Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3 K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 78:356–365\nLi XF, Charnock-Jones DS, Zhang E, Hiby S, Malik S, Day K, Licence D, Bowen JM, Gardner L, King A, Loke YW, Smith SK (2001) Angiogenic growth factor messenger ribonucletic acids in uterine natural killer cells. J Clin Endocrinol Metab 86:1823–1834\nMoller B, Lindblom B, Olovsson M (2002) Expression of the vascular endothelial growth factors B and C and their receptor in human endometrium during the menstrual cycle. Acta Obstet Gynecol Scand 81:817–824\nTakehara M, Ueda M, Yamashita Y, Terai Y, Hung YC, Ueki M (2004) Vascular endothelial growth factor A and C gene expression in endometriosis. Hum Pathol 35:1369–1375\nReichelt U, Keichel S, Barcena de Arellano ML, Chiantera V, Schneider A, Mechsner S (2012) High lymph vessel density and expression of lymphatic growth factors in peritoneal endometriosis. Reprod Sci. doi:10.1177/1933719112438440\nWitzenbichler B, Asahara T, Murohara T, Silver M, Spyridopoulos I, Magner M, Principe N, Kearney M, Hu JS, Isner JM (1998) Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 153:381–394\nZeng Y, Opeskin K, Goad J, Williams ED (2006) Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis. Cancer Res 66:9566–9575\nLin CI, Chen CN, Huang MT, Lee SJ, Lin CH, Chang CC, Lee H (2008) Lysophosphatidic acid up-regulates vascular endothelial growth factor-C and lymphatic marker expressions in human endothelial cells. Cell Mol Life Sci 65:2740–2751\nRice VM (2002) Conventional medical therapies for endometriosis. Ann N Y Acad Sci 955:343–352\nXu H, Wang CC (2010) Angiogenesis and Anti-angiogenesis Therapy of Endometriosis. In: Mitchell LA (ed) Endometriosis: symptoms, diagnosis and treatments. Nova Science, New York. Chapter 1, pp. 1–40\nDabrosin C, Gyorffy S, Margetts P, Ross C, Gauldie J (2002) Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. Am J Pathol 161:909–918\nYagyu T, Kobayashi H, Matsuzaki H, Wakahara K, Kondo T, Kurita N, Sekino H, Inagaki K, Suzuki M, Kanayama N, Terao T (2005) Thalidomide inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-kappaB activation. J Clin Endocrinol Metab 90:3017–3021\nScarpellini F, Sbracia M, Lecchini S, Scarpellini L (2002) Anti-angiogenesis treatment with thalidomide in endometriosis: a pilot study. Fertil Steril 78:S87\nNyberg P, Xie L, Kalluri R (2005) Endogenous inhibitors of angiogenesis. Cancer Res 65:3967–3979\nKlauber N, Rohan RM, Flynn E, D’Amato RJ (1997) Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat Med 3:443–446\nAcknowledgments\nSpecial thanks to Muna El-Kasti, Elizabeth Rapa and Dionne Tanetta for assistance with the culture experiments. This work was supported by the Global Scholarship Programme for Research Excellence-CNOOC grant 2008–2009 from the Chinese University of Hong Kong to H.X. and C.C.W. to conduct experiments at Harvard and Oxford Universities; an Incentive Scheme on Research Performance from the Chinese University of Hong Kong to T.Z. for PhD study; a Hong Kong Obstetrical and Gynaecological Trust Fund 2010 grant from the Obstetrical and Gynaecological Society of Hong Kong to C.C.W. and G.C.W.G.; a General Research Fund 2012/2013 (CUHK475012) from Hong Kong Research Grants Council to C.C.W, C.M.B. and A.L.K.; a MRC New Investigator Award (G0601458) and the Oxford Partnership Comprehensive Biomedical Research Centre from the Department of Health’s NIHR Biomedical Research Centres scheme to C.M.B.; a MRC Doctoral Training Account (DTA) and an Oxfordshire Health Services Research Committee Grant to K.E.M.\nConflict of interest\nThe authors declare there is no conflict of interest.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nXu, H., Zhang, T., Man, G.C.W. et al. Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis. Angiogenesis 16, 541–551 (2013). https://doi.org/10.1007/s10456-013-9333-1\nReceived:\nAccepted:\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s10456-013-9333-1","source_license":"CC0","license_restricted":false}